Implementation of a weight-based, dose-capping protocol for nivolumab resulted in substantial cost savings at a large, tertiary care hospital in Miami.
Results of a study comparing costs of the previous flat-dose approach of 240 mg with a weight-based strategy capped at 240 mg showed savings of nearly 10% per dose ($7,352.62 vs. $6,634.01). According to data presented at the 2019 Hematology/Oncology Pharmacy Association (HOPA) annual meeting